• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

    4/21/25 7:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care
    Get the next $BLCO alert in real time by email

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE Recycling and Biotrue Eye Care Recycling programs have collected a total of 103,169,500 units, or 625,026 pounds, of used contact lenses, eye care and lens care materials in the United States. That's equivalent to the weight of approximately 600 concert grand pianos1.

    "These award-winning recycling programs continue to drive a positive environmental impact, offering eye care professionals, patients and consumers a way to properly recycle used eye health materials," said Amy Butler, Vice President, Global Environment, Health, Safety and Sustainability, Bausch + Lomb.

    Due to their small size and the type of plastic used to manufacture them, contact lenses, eye care and lens care materials are often inefficiently processed in standard recycling facilities and may inadvertently end up in landfills or waterways. In the U.S., it is estimated that six to 10 metric tons of contact lenses end up in wastewater each year, polluting aquatic environments and potentially impacting the human food supply.

    "The ONE by ONE and Biotrue Eye Care Recycling programs allow my practice and patients to responsibly recycle eye health items—something that wasn't possible until these programs became available," said Jennifer Tsai, OD, LINE OF SIGHT, New York. "We're proud to collect these materials and contribute to a cleaner environment and healthier planet."

    The ONE by ONE Recycling program has collected over 101 million used contact lenses, blister packs and top foils since the program's launch in November 2016. The Biotrue Eye Care Recycling program, which launched in April 2021, has collected over 1.3 million eye drop single dose units, lens cases and lens solution caps, as well as all Biotrue-branded eye drop bottles2. Bausch + Lomb has a similar contact lens recycling program in Canada called Every Contact Counts.

    Bausch + Lomb is committed to implementing, maintaining and enhancing sustainable business practices that support customers, consumers, eye care professionals, patients, employees and communities around the world. Its impact initiatives are measured against several key environmental metrics called "FEWW" – fuel, energy, water and waste. Each Bausch + Lomb facility has annualized goals against these metrics to harness new opportunities and evolve in a sustainable way as the company delivers on its mission of helping people see better to live better. Visit www.bausch.com/impact for more information.

    ###

    About the ONE by ONE Recycling Program

    The Bausch + Lomb ONE by ONE Recycling program is the first and only contact lens recycling program in the United States. This program collects used contact lenses, top foils and opened plastic blister packs from any brand and is available to contact lens wearers and eye care professionals. To participate, contact lens wearers can bring their used contact lenses and packaging to one of these practices, which collect the used materials in a custom recycling bin provided by Bausch + Lomb. Once the bin is filled, the eye care practice ships the materials using a Bausch + Lomb pre-paid shipping label to TerraCycle® where lenses are cleaned and melted into hard plastic pellets that can be used to make new recycled products. To learn more about the Bausch + Lomb ONE by ONE Recycling program, visit www.bauschrecycles.com.

    About the Biotrue Eye Care Recycling Program

    The Bausch + Lomb Biotrue Eye Care Recycling program is the first and only eye care and lens care recycling program in the United States. This program allows consumers who participate to properly recycle all brands of eye drop single dose units, lens cases and lens solution caps, as well as all Biotrue-branded eye drop bottles. Once consumers collect these items, they can be mailed to TerraCycle using a pre-paid shipping label. When the waste arrives at the TerraCycle facility, it is cleaned and melted into hard plastic pellets that can be used to make new recycled products. To learn more about the Biotrue Eye Care Recycling program, visit www.biotrue.com/terracycle/.

    About Bausch + Lomb

    Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

    References

    1. https://www.pianosolutions.net/piano-sizes.htm
    2. Contact lens solution bottles are recyclable through standard recycling

    TerraCycle® is a trademark of TerraCycle Inc. used under license.

    ©2025 Bausch + Lomb.

    BIO.0018.USA.25

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250421299221/en/

    Media:

    Kristy Marks

    [email protected]

    (908) 927-0683

    Get the next $BLCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLCO

    DatePrice TargetRatingAnalyst
    1/5/2026$18.00Outperform → In-line
    Evercore ISI
    12/11/2025$20.00Neutral → Buy
    Citigroup
    12/2/2025$21.00Equal-Weight → Overweight
    Morgan Stanley
    10/1/2025$16.00Neutral
    Goldman
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BLCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and CFO Eldessouky Sam bought $68,520 worth of shares (4,000 units at $17.13) and was granted 4,000 shares, increasing direct ownership by 2% to 407,130 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 4:34:11 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    CEO and Chairman of the Board Saunders Brent L bought $251,958 worth of shares (14,700 units at $17.14) and was granted 14,700 shares, increasing direct ownership by 3% to 981,275 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 4:32:06 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Director Ross Thomas W. Sr. bought $79,556 worth of shares (4,500 units at $17.68) and was granted 4,500 shares, increasing direct ownership by 15% to 69,391 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/4/26 4:18:54 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bausch + Lomb downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Bausch + Lomb from Outperform to In-line and set a new price target of $18.00

    1/5/26 8:46:17 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb upgraded by Citigroup with a new price target

    Citigroup upgraded Bausch + Lomb from Neutral to Buy and set a new price target of $20.00

    12/11/25 8:44:49 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Bausch + Lomb from Equal-Weight to Overweight and set a new price target of $21.00

    12/2/25 8:17:09 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bausch + Lomb Corporation

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 5:23:22 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    EVP and CFO Eldessouky Sam bought $68,520 worth of shares (4,000 units at $17.13) and was granted 4,000 shares, increasing direct ownership by 2% to 407,130 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 4:34:11 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    CEO and Chairman of the Board Saunders Brent L bought $251,958 worth of shares (14,700 units at $17.14) and was granted 14,700 shares, increasing direct ownership by 3% to 981,275 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 4:32:06 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, April 29, 2025 Time: 8 a.m. ET Webcast: https://www.webcaster5.com/Webcast/Page/2883/53393 Participant Event Dial-in: +1 (888) 506-

    3/30/26 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma

    Both primary effectiveness endpoints were met, demonstrating statistically significant and clinically meaningful intraocular pressure reduction. ELIOS is an implant-free procedure that uses excimer laser technology for the treatment of glaucoma. Topline results will be discussed at 1:30 p.m. ET today on the inaugural Bausch + Lomb R&D Teach-in Webinar (register here). Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced positive 24-month results from the pivotal U.S. clinical trial of the ELIOS System. Developed for the treatment of elevated intraocular pressure (IOP) in patients with

    3/23/26 7:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Launches R&D "Teach-in" Webinar Series

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D "Teach-in" webinar series that will provide deeper insights on the company's differentiated product pipeline, which was unveiled in November 2025. On Monday, March 23, 2026, at 1:30 p.m. ET, Executive Vice President of Research & Development and Chief Medical Officer Yehia Hashad, MD, will be joined by members of his leadership team to discuss two glaucoma assets: BL1107, a glaucoma medication under development that would be the first to treat vision loss in addition to lowering intraocular pressure ELIOS™, an

    3/9/26 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    SEC Filings

    View All

    SEC Form 10-K filed by Bausch + Lomb Corporation

    10-K - Bausch & Lomb Corp (0001860742) (Filer)

    2/18/26 5:19:06 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    2/18/26 7:01:45 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    1/2/26 4:10:34 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bausch + Lomb Corporation

    SC 13G - Bausch & Lomb Corp (0001860742) (Subject)

    2/14/23 5:14:30 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Leadership Updates

    Live Leadership Updates

    View All

    Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

    Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For   Against   Broker Non-Votes Nathalie Bernier   337,617,248   1,924,336   8,383,437 Gary Hu   337,591,706   1,949,878   8,383,437 Brett Icahn   337,474,287   2,067,297   8,383,437 Sarah B. Kavanagh   337,602,211   1,939,373  

    5/21/25 4:30:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

    Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,

    2/28/24 8:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

    Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai

    2/21/24 7:00:00 AM ET
    $BLCO
    $EBS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BLCO
    Financials

    Live finance-specific insights

    View All

    Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, April 29, 2025 Time: 8 a.m. ET Webcast: https://www.webcaster5.com/Webcast/Page/2883/53393 Participant Event Dial-in: +1 (888) 506-

    3/30/26 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

    Delivered meaningful EBITDA margin expansion and operating leverage in the fourth quarter Fourth-Quarter 2025 Financial Results Revenue of $1.405 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $58 Million Adjusted EBITDA (non-GAAP)1 of $326 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $330 Million Revenue Grew 10% as Reported and 7% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2024 Full-Year 2025 Financial Results Revenue of $5.101 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $360 Million Adjusted EBITDA (non-GAAP)1 of $858 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1

    2/18/26 6:58:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, Feb. 18, 2026   Time: 8:00 a.m. ET   Webcast: https://www.webcaster5.com/Webcast/Page/2883/53392   Pa

    1/20/26 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care